

# Bicycle

## Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

November 10, 2022

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Nov. 10, 2022-- [Bicycle Therapeutics plc](#) (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*®) technology, today announced that preclinical data for BT7480, a novel *Bicycle* tumor-targeted immune cell agonist (*Bicycle* TICA), and BT7455, an EphA2/CD137 *Bicycle* TICA, will be presented in five poster presentations at the Society for Immunotherapy of Cancer's (SITC) 37<sup>th</sup> Annual Meeting, being held in Boston, M.A. and virtually on November 8-12, 2022. Details on Bicycle's poster presentations at SITC are as follows:

**Poster Title:** NKp46 engaging Bicycle NK-TICA® drives tumor targeted cytotoxicity

**Presenter:** Alexandra Rezvaya, Bicycle Therapeutics

**Session Title:** Immuno-conjugates and chimeric molecules

**Poster #:** 1207

**Date and Time:** Thursday, November 10 at 9 a.m. ET

**Poster Title:** Utility of humanized animal models for in vivo evaluation of NK-TICA®, novel Bicycle tumor-targeted immune cell agonist® (Bicycle TICA®) designed to engage NK cells

**Presenter:** Lukas Stanczuk, Bicycle Therapeutics

**Session Title:** Novel single-agent immunotherapies

**Poster #:** 1388

**Date and Time:** Friday, November 11 at 9 a.m. ET

**Poster Title:** Transcriptional profiling of Bicycle® tumor-targeted CD137 agonist-treated mouse tumors revealed an early and rapid activation of myeloid cells followed by infiltration of cytotoxic T cells into the tumor

**Presenter:** Johanna Lahdenranta, Bicycle Therapeutics

**Session Title:** Novel single-agent immunotherapies

**Poster #:** 1356

**Date and Time:** Friday, November 11 at 9 a.m. ET

**Poster Title:** BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy

**Presenters:** Kristin Hurov and Lia Luus, Bicycle Therapeutics

**Session Title:** Novel single-agent immunotherapies

**Poster #:** 1340

**Date and Time:** Friday, November 11 at 9 a.m. ET

**Poster Title:** In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems for industry

**Presenter:** Anna Licht, Bicycle Therapeutics

**Session Title:** Immune cell types and biology

**Poster #:** 980

**Date and Time:** Friday, November 11 at 9 a.m. ET

The poster presentations are available on the Publications section of [bicycletherapeutics.com](#).

### About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit [bicycletherapeutics.com](#).

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20221110005380/en/>

### Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

[david.borah@bicyclerx.com](mailto:david.borah@bicyclerx.com)

617-203-8300

**Media:**

Argot Partners

Sarah Sutton

[bicycle@argotpartners.com](mailto:bicycle@argotpartners.com)

212-600-1902

Source: Bicycle Therapeutics